IP Library Granted Patent US 12,533,356
Granted Patent B2
US 12,533,356 · App. 18/463,865 · Granted Jan 27, 2026

Pyrazolopyrimidine compounds as adenosine receptor antagonists

Inventors: Andrew Simon Bell (Dundee, GB); Adrian Michael Schreyer (Dundee, GB); Stephanie Versluys (Toulouse, FR)
Assignees: EVOTECH INTERNATIONAL GMBH; RECURSION PHARMACEUTICALS, INC.
A61K31/519A61P35/00C07D487/04G01N33/566
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,533,356
App. No.
18/463,865
Granted
Jan 27, 2026
Kind
B2
Abstract

The invention provides a compound of formula (I), or pharmaceutically acceptable ester, amide, carbamate, solvate or salt thereof, including a salt of such an ester, amide or carbamate, wherein R 1 is an optionally substituted phenyl, or an optionally substituted 5- or 6-membered aromatic heterocycle; and R 2 is an optionally substituted 5- or 6-membered aromatic heterocycle. Also provided are pharmaceutical compositions comprising a compound of formula (I).

Claims (63)

1 . A compound of formula (I), or pharmaceutically acceptable ester, amide, carbamate, solvate or salt thereof, including a salt of such an ester, amide or carbamate,

wherein R 1 is an optionally substituted phenyl, or an optionally substituted 5- or 6-membered aromatic heterocycle comprising 1, 2 or 3 heteroatoms independently selected from the group consisting of N, S and O, wherein said phenyl is optionally substituted with 1, 2 or 3 substituents, each substituent being independently selected from the group consisting of fluorine, meta-chlorine, para-chorine, OH, C 1-8 alkyl, C 1-8 alkyl substituted with 1, 2 or 3 halogens or OH groups, OC 1-8 alkyl, and OC 1-8 alkyl substituted with 1, 2 or 3 halogens or OH groups, and wherein said 5- or 6-membered aromatic heterocycle is optionally substituted with 1, 2 or 3 substituents, each substituent being independently selected from the group consisting of halogen, OH, C 1-8 alkyl, C 1-8 alkyl substituted with 1, 2 or 3 halogens or OH groups, OC 1-8 alkyl, and OC 1-8 alkyl substituted with 1, 2 or 3 halogens or OH groups; and

R 2 is an optionally substituted 5- or 6-membered aromatic heterocycle comprising 2 or 3 heteroatoms independently selected from the group consisting of N, S and O, wherein said 5- or 6-membered aromatic heterocycle is optionally substituted with 1, 2 or 3 substituents, each substituent being independently selected from the group consisting of C 1-3 alkyl and C 1 -3alkyl substituted with 1, 2 or 3 halogens.

2 . A compound as claimed in claim 1 , wherein R 1 is an optionally substituted phenyl, or an optionally substituted 5- or 6-membered aromatic heterocycle comprising 1 or 2 heteroatoms independently selected from the group consisting of N and S.

3 . A compound as claimed in claim 1 , wherein when R 1 is a substituted phenyl, said phenyl is substituted with 1, 2 or 3 substituents, each substituent being independently selected from the group consisting of halogen (preferably F or Cl, and more preferably F or meta or para Cl), C 1-8 alkyl, C 1-8 alkyl substituted with 1, 2 or 3 halogens (preferably F) or OH groups, OC 1-8 alkyl, and OC 1-8 alkyl substituted with 1, 2 or 3 halogens (preferably F).

4 . A compound as claimed in claim 1 , wherein when R 1 is a substituted phenyl, said phenyl is substituted with 1 or 2 substituents, each substituent being independently selected from the group consisting of C 1-4 alkyl, C 1-4 alkyl substituted with 1, 2 or 3 halogens (preferably F) or OH groups, OC 1-4 alkyl, and OC 1-4 alkyl substituted with 1, 2 or 3 halogens (preferably F) or OH groups.

5 . A compound as claimed in claim 1 , wherein when R 1 is a substituted phenyl, said phenyl is substituted with 1 or 2 substituents, each substituent being independently selected from the group consisting of F, meta-chlorine, para-chorine, C 1-4 alkyl, C 1-4 alkyl substituted with 1, 2 or 3 halogens (preferably F) or OH groups, and OC 1-4 alkyl; and more preferably each substituent being independently selected from the group consisting of halogen (e.g. F or Cl), C 1-4 alkyl, C 1-4 alkyl substituted with 1 OH group and OC 1-4 alkyl.

6 . A compound as claimed in claim 1 , wherein R 1 is a substituted phenyl.

7 . A compound as claimed in claim 1 , wherein R 2 is an optionally substituted 5- or 6-membered aromatic heterocycle comprising 2 or 3 heteroatoms independently selected from the group consisting of N, S and O, wherein at least one of the heteroatoms is N.

8 . A compound as claimed in claim 1 , wherein R 2 is an optionally substituted 5- or 6-membered aromatic heterocycle selected from the group consisting of imidazolyl (1,3-diazolyl), pyrazolyl (1,2-diazolyl), 1,3-oxazolyl, isoxazolyl (1,2-oxazolyl), thiazolyl (1,3-thiazolyl), isothiazolyl (1,2-thiazolyl), 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, 1H-1,2,4-triazolyl, 4H-1,2,4-triazolyl, furazanyl (1,2,5-oxadiazolyl), 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, pyridazinyl (1,2-diazinyl), pyrimidinyl (1,3-diazinyl), pyrazinyl (1,4-di azirtyl), 1,2,3-triazinyl, 1,2,4-triazinyl, and 1,3,5-triazinyl; or

wherein R 2 is an optionally substituted 5- or 6-membered aromatic heterocycle selected from the group consisting of 1,3-oxazolyl, isoxazolyl (1,2-oxazolyl), thiazolyl (1,3-thiazolyl), isothiazolyl (1,2-thiazolyl), 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, pyridazinyl (1,2-diazinyl), pyrimidinyl (1,3-diazinyl), and pyrazinyl (1,4-diazinyl).

9 . A compound as claimed in claim 1 , wherein R 2 is an optionally substituted 5- or 6-membered aromatic heterocycle selected from the group consisting of imidazolyl (1,3-diazolyl), pyrazolyl (1,2-diazolyl), 1,3-oxazolyl, isoxazolyl (1,2-oxazolyl), thiazol-2-yl (1,3-thiazol-2-yl), isothiazolyl (1,2-thiazolyl), 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, 1H-1,2,4-triazolyl, 4H-1,2,4-triazolyl, furazanyl (1,2,5-oxadiazolyl), 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, pyridazinyl (1,2-diazinyl), pyrimidinyl (1,3-diazinyl), pyrazinyl (1,4-diazinyl), 1,2,3-triazinyl, 1,2,4-triazinyl, and 1,3,5-triazinyl; or

wherein R 2 is an optionally substituted 5- or 6-membered aromatic heterocycle selected from the group consisting of 1,3-oxazolyl, isoxazolyl (1,2-oxazolyl), thiazol-2-yl (1,3-thiazol-2-yl), isothiazolyl (1,2-thiazolyl), 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, pyridazinyl (1,2-diazinyl), pyrimidinyl (1,3-diazinyl), and pyrazinyl (1,4-diazinyl).

10 . A compound as claimed in claim 1 , wherein, R 2 is an optionally substituted 5- or 6-membered aromatic heterocycle, and wherein said 5- or 6-membered aromatic heterocycle is optionally substituted with 1 or 2 substituents (preferably 1 substituent), each substituent being independently selected from the group consisting of C 1-3 alkyl and C 1-3 alkyl substituted with 1, 2 or 3 fluorines; and preferably each substituent is methyl; or

wherein R 2 is an unsubstituted 5- or 6-membered aromatic heterocycle.

11 . A compound as claimed in claim 1 , wherein the compound is selected from the group consisting of

2-[(3-methylphenyl)methyl]-6-(1,2-thiazol-3-yl)-2H-pyrazolo[3,4-d]pyrimidin-4-amine;

2-[(3-methoxyphenyl)methyl]-6-(pyrazin-2-yl)-2H-pyrazolo[3,4-d]pyrimidin-4-amine;

3-{[4-amino-6-(pyrazin-2-yl)-2H-pyrazolo[3,4-d]pyrimidin-2-yl]methyl}phenol;

2-[(3-methoxyphenyl)methyl]-6-(1,3-oxazol-2-yl)-2H-pyrazolo[3,4-d]pyrimidin-4-amine;

2-[(3-methoxyphenyl)methyl]-6-(4-methyl-1,3-thiazol-2-yl)-2H-pyrazolo[3,4-d]pyrimidin-4-amine;

2-[(3-methoxyphenyl)methyl]-6-(3-methyl-1,2-oxazol-5-yl)-2H-pyrazolo[3,4-d]pyrimidin-4-amine;

2-[(3-methoxyphenyl)methyl]-6-(4-methyl-1,2,3-thiadiazol-5-yl)-2H-pyrazolo[3,4-d]pyrimidin-4-amine;

2-[(3-methoxyphenyl)methyl]-6-(1,3-thiazol-2-yl)-2H-pyrazolo[3,4-d]pyrimidin-4-amine;

2-[(3-methoxyphenyl)methyl]-6-(1,3-thiazol-4-yl)-2H-pyrazolo[3,4-d]pyrimidin-4-amine;

2-[(3-methoxyphenyl)methyl]-6-(1,2-thiazol-3-yl)-2H-pyrazolo[3,4-d]pyrimidin-4-amine;

2-[(3-methoxyphenyl)methyl]-6-(1,3-oxazol-5-yl)-2H-pyrazolo[3,4-d]pyrimidin-4-amine;

2-[(4-methylphenyl)methyl]-6-(pyrazin-2-yl)-2H-pyrazolo[3,4-d]pyrimidin-4-amine;

2-[(4-methylphenyl)methyl]-6-(1,2-thiazol-3-yl)-2H-pyrazolo[3,4-d]pyrimidin-4-amine;

2-[(4-methylphenyl)methyl]-6-(1,3-thiazol-2-yl)-2H-pyrazolo[3,4-d]pyrimidin-4-amine;

2-[(4-methoxyphenyl)methyl]-6-(pyrazin-2-yl)-2H-pyrazolo[3,4-d]pyrimidin-4-amine;

6-(1,2-thiazol-3-yl)-2-{[3-(trifluoromethoxy)phenyl]methyl}-2H-pyrazolo[3,4-d]pyrimidin-4-amine;

6-(1,2-thiazol-3-yl)-2-{[4-(trifluoromethyl)phenyl]methyl}-2H-pyrazolo[3,4-d]pyrimidin-4-amine;

2-[(3-methoxy-4-methylphenyl)methyl]-6-(1,2-thiazol-3-yl)-2H-pyrazolo[3,4-d]pyrimidin-4-amine;

2-[(3-fluoro-4-methylphenyl)methyl]-6-(1,2-thiazol-3-yl)-2H-pyrazolo[3,4-d]pyrimidin-4-amine;

2-[(3,4-dimethylphenyl)methyl]-6-(1,2-thiazol-3-yl)-2H-pyrazolo[3,4-d]pyrimidin-4-amine;

2-[(pyridin-2-yl)methyl]-6-(1,2-thiazol-3-yl)-2H-pyrazolo[3,4-d]pyrimidin-4-amine;

2-[(6-methylpyridin-3-yl)methyl]-6-(1,2-thiazol-3-yl)-2H-pyrazolo[3,4-d]pyrimidin-4-amine;

2-{[4-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(1,2-thiazol-3-yl)-2H-pyrazolo[3,4-d]pyrimidin-4-amine;

2-[(2-methoxy-4-methylphenyl)methyl]-6-(1,2-thiazol-3-yl)-2H-pyrazolo[3,4-d]pyrimidin-4-amine;

2-[(3-methylphenyl)methyl]-6-(1,3-oxazol-2-yl)-2H-pyrazolo[3,4-d]pyrimidin-4-amine;

2-[(3-methylphenyl)methyl]-6-(pyrazin-2-yl)-2H-pyrazolo[3,4-d]pyrimidin-4-amine;

6-(pyrazin-2-yl)-2-{[3-(trifluoromethyl)phenyl]methyl}-2H-pyrazolo[3,4-d]pyrimidin-4-amine;

2-[(3-fluorophenyl)methyl]-6-(1,2-thiazol-3-yl)-2H-pyrazolo[3,4-d]pyrimidin-4-amine;

2-[(3-fluorophenyl)methyl]-6-(pyrazin-2-yl)-2H-pyrazolo[3,4-d]pyrimidin-4-amine;

2-[(2-methylphenyl)methyl]-6-(pyrazin-2-yl)-2H-pyrazolo[3,4-d]pyrimidin-4-amine;

2-[(2-methylphenyl)methyl]-6-(1,2-thiazol-3-yl)-2H-pyrazolo[3,4-d]pyrimidin-4-amine;

6-(1,3-thiazol-2-yl)-2-[(1,3-thiazol-2-yl)methyl]-2H-pyrazolo[3,4-d]pyrimidin-4-amine;

2-[(1,3-thiazol-2-yl)methyl]-6-(1,2-thiazol-3-yl)-2H-pyrazolo[3,4-d]pyrimidin-4-amine;

2-[(3-chlorophenyl)methyl]-6-(1,2-thiazol-3-yl)-2H-pyrazolo[3,4-d]pyrimidin-4-amine;

2-[(3-chlorophenyl)methyl]-6-(pyrazin-2-yl)-2H-pyrazolo[3,4-d]pyrimidin-4-amine;

2-[(2-methoxyphenyl)methyl]-6-(pyrazin-2-yl)-2H-pyrazolo[3,4-d]pyrimidin-4-amine;

2-[(2-methoxyphenyl)methyl]-6-(1,2-thiazol-3-yl)-2H-pyrazolo[3,4-d]pyrimidin-4-amine;

2-[(2-methoxyphenyl)methyl]-6-(1,3-oxazol-2-yl)-2H-pyrazolo[3,4-d]pyrimidin-4-amine;

2-[(2-methoxyphenyl)methyl]-6-(1,3-oxazol-5-yl)-2H-pyrazolo[3,4-d]pyrimidin-4-amine;

2-[(3,4-dimethoxyphenyl)methyl]-6-(pyrazin-2-yl)-2H-pyrazolo[3,4-d]pyrimidin-4-amine;

3-{[4-amino-6-(1,2-thiazol-3-yl)-2H-pyrazolo[3,4-d]pyrimidin-2-yl]methyl}phenol;

2-{[4-amino-6-(1,2-thiazol-3-yl)-2H-pyrazolo[3,4-d]pyrimidin-2-yl]methyl}-5-methylphenol;

2-{[4-amino-6-(1,2-thiazol-3-yl)-2H-pyrazolo[3,4-d]pyrimidin-2-yl]methyl}phenol;

5-{[4-amino-6-(1,2-thiazol-3-yl)-2H-pyrazolo[3,4-d]pyrimidin-2-yl]methyl}-2-methylphenol; and

[3-[(4-amino-6-(1,2-thiazol-3-yl)-pyrazolo[3,4-d]pyrimidin-2-yl)methyl]phenyl]methanol;

or pharmaceutically acceptable ester, amide, carbamate, solvate or salt thereof, including a salt of such an ester, amide or carbamate.

12 . A pharmaceutical composition which comprises a compound as claimed in claim 1 , together with a pharmaceutically suitable carrier, and optionally also comprises a further therapeutic agent.

Assignments (3)
CHANGE OF NAME Recorded Mar 12, 2025
From: EXSCIENTIA LTD.
To: EXSCIENTIA AI LIMITED
Reel/Frame 070494/0494 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 12, 2025
From: EXSCIENTIA AI LIMITED; EXSCIENTIA GMBH
To: RECURSION PHARMACEUTICALS, INC.
Reel/Frame 070490/0005 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 8, 2023
From: BELL, ANDREW SIMON; SCHREYER, ADRIAN MICHAEL; VERSLUYS, STEPHANIE
To: EXSCIENTIA LTD.; EVOTEC INTERNATIONAL GMBH
Reel/Frame 064850/0547 →
Priority Claims (1)
EP 18290061 · Jun 4, 2018 · regional
Continuity (2)
Continuation 15734074
Related Publication 20240108624A1 · Apr 4, 2024
References Cited (83)
US 8283476B2 · Halland · 2012 [cited by applicant]
US 9353116B2 · Garske · 2016 [cited by applicant]
US 9365574B2 · Raghavan · 2016 [cited by applicant]
US 9580416B2 · Chen · 2017 [cited by applicant]
US 10519160B2 · Van De Bittner · 2019 [cited by applicant]
US 11786528B2 · Bell · 2023 [cited by examiner]
US 20030114467A1 · Shakespeare · 2003 [cited by applicant]
US 20070004761A1 · Basarab · 2007 [cited by applicant]
US 20100273776A1 · Lindquist · 2010 [cited by applicant]
US 20100331297A1 · Bulawa · 2010 [cited by applicant]
US 20150315198A1 · Li et al. · 2015 [cited by applicant]
US 20200299285A1 · Fletcher · 2020 [cited by applicant]
US 20220168315A1 · Bajji · 2022 [cited by applicant]
CN 112608318A · 2021 [cited by applicant]
EP 1949903B1 · 2012 [cited by applicant]
IT 2007RM0480 · 2007 [cited by applicant]
WO WO9746560 · 1997 [cited by applicant]
WO WO2005049616A1 · 2005 [cited by applicant]
WO WO2008141385A1 · 2008 [cited by applicant]
WO WO2011121418A1 · 2011 [cited by applicant]
WO WO2011050245A1 · 2011 [cited by applicant]
WO WO2011153588A1 · 2011 [cited by applicant]
WO WO2013106254A1 · 2013 [cited by applicant]
WO WO2014126580A1 · 2014 [cited by applicant]
WO WO2017025918A1 · 2017 [cited by applicant]
WO WO2017112917 · 2017 [cited by applicant]
WO WO2021121397A1 · 2021 [cited by applicant]
WO WO2022125377A1 · 2022 [cited by applicant]
WO WO2022268209A1 · 2022 [cited by applicant]
International Search Report issued in International Application No. PCT/EP2019/064450, mailed Nov. 19, 2019. [cited by applicant]
Written Opinion of the International Searching Authority issued in International Application No. PCT/EP2019/064450, mailed Nov. 19, 2019. [cited by applicant]
Database Registry, [Online], Chemical Abstracts Service, Columbus, Ohio, US; Jan. 30, 2017 (Jan. 30, 2017), XP002784453, Database accession No. 2061415-13-0, Chemical Library, Supplier: Aurora Fine, Chemicals; RNs 20614… [cited by applicant]
Database Registry [Online], Chemical Abstracts Service, Columbus. Ohio, US; Jan. 31, 2017 (Jan. 31, 2017), XP002784454, Database accession No. 2062036-96-6 Chemical Library, Supplier: Aurora Fine, Chemicals; RN 2062036-… [cited by applicant]
Squarcialupi Lucia et al: “Exploring the 2- and 5-positions of the pyrazolo[4,3-d]pyrimidin-7-amino scaffold to target human A1and A2Aadenosine receptors”, Bioorganic & Medicinal Chemistry, Pergamon, GB, vol. 24, No. 12… [cited by applicant]
Sabrina Taliani et al: “Novel N 2-Substituted Pyrazolo[3,4-d ]pyrimidine Adenosine A 3 Receptor Antagonists: Inhibition of A 3-Mediated Human Glioblastoma Cell Proliferation +”. Journal of Medicinal Chemistry, vol. 53, … [cited by applicant]
Congreve et al., J. Med. Chem., 2012, 55, 1898-1903. [cited by applicant]
Supplementary information for Congreve et al., J. Med. Chem., 2012, 55, 1898-1903. [cited by applicant]
Jazeyri et al., Chem. Rev., 2017, 117, 1, 21-37. [cited by applicant]
Jenner, “An Overview of Adenosine A2A Receptor Antagonists in Parkinson's Disease”, Int. Rev. Neurobiol., 2014, 119, chapter 3, 71-86. [cited by applicant]
Mediavilla-Varela, M et al Neoplasia 2017 19 530. [cited by applicant]
Squarcialupi et al., Biorganic and Medicinal Chemistry, 2016, 24, 2794-2808. [cited by applicant]
Squarcialupi et al., Eur. J. Med. Chem., 2014, 84, 614-627. [cited by applicant]
Stagg and Smyth, Oncogene, 2010, 29(39), 5346-5358. [cited by applicant]
Young et al., Cancer Discovery, 2014, 4, 879-888. [cited by applicant]
Taliani et al., J. Med. Chem., 2010, 53, 3954-3963. [cited by applicant]
Indian Office Action mailed Jun. 6, 2022 in counterpart Indian Application No. 202047052525. [cited by applicant]
Russian Office Action mailed Dec. 8, 2022 in counterpart Russian Application No. 2020140644/04 (075638) with machine English language translation. [cited by applicant]
Office Action issued in counterpart Japanese Application No. 2020-567151, mailed Apr. 26, 2023 with English language translation thereof. [cited by applicant]
Da Settimo, F., et al., Journal of Medicinal Chemistry, 2005, vol. 48, No. 16, pp. 5162-5174. [cited by applicant]
Catalogue compounds located by FTO search. [cited by applicant]
2061 41 5-1 3-0 entered in STN on Jan. 31, 2017 (Year: 2017). [cited by applicant]
2061415-07-2 entered in STN on Jan. 31, 2017 (Year: 2017). [cited by applicant]
2062036-96-6 entered in STN on Jan. 31, 2017 (Year: 2017). [cited by applicant]
STN Registry No. 2062318-40-3, Entry date: Jan. 31, 2017. [cited by applicant]
STN Registry No. 2062315-34-6, Entry date: Jan. 31, 2017. [cited by applicant]
STN Registry No. 2062189-55-1, Entry date: Jan. 31, 2017. [cited by applicant]
STN Registry No. 2062188-58-1, Entry date: Jan. 31, 2017. [cited by applicant]
STN Registry No. 2062187-98-6, Entry date: Jan. 31, 2017. [cited by applicant]
STN Registry No. 2062036-51-3, Entry date: Jan. 31, 2017. [cited by applicant]
STN Registry No. 2062035-90-7, Entry date: Jan. 31, 2017. [cited by applicant]
STN Registry No. 2062035-52-1, Entry date: Jan. 31, 2017. [cited by applicant]
STN Registry No. 2062034-99-3, Entry date: Jan. 31, 2017. [cited by applicant]
STN Registry No. 2061419-51-8, Entry date: Jan. 30, 2017. [cited by applicant]
STN Registry No. 2061419-50-7, Entry date: Jan. 30, 2017. [cited by applicant]
STN Registry No. 2061153-17-9, Entry date: Jan. 29, 2017. [cited by applicant]
STN Registry No. 2061152-90-5, Entry date: Jan. 29, 2017. [cited by applicant]
STN Registry No. 2061152-78-9, Entry date: Jan. 29, 2017. [cited by applicant]
STN Registry No. 2061152-40-5, Entry date: Jan. 29, 2017. [cited by applicant]
STN Registry No. 2060788-14-7, Entry date: Jan. 29, 2017. [cited by applicant]
STN Registry No. 2060527-91-3, Entry date: Jan. 27, 2017. [cited by applicant]
STN Registry No. 2060527-83-3, Entry date: Jan. 27, 2017. [cited by applicant]
STN Registry No. 2060527-77-5, Entry date: Jan. 27, 2017. [cited by applicant]
STN Registry No. 2060527-47-9, Entry date: Jan. 27, 2017. [cited by applicant]
STN Registry No. 2060525-12-2, Entry date: Jan. 27, 2017. [cited by applicant]
STN Registry No. 2059790-31-5, Entry date: Jan. 26, 2017. [cited by applicant]
STN Registry No. 2059787-88-9, Entry date: Jan. 26, 2017. [cited by applicant]
STN Registry No. 2059787-87-8, Entry date: Jan. 26, 2017. [cited by applicant]
STN Registry No. 2059177-25-0, Entry date: Jan. 25, 2017. [cited by applicant]
STN Registry No. 2058942-99-5, Entry date: Jan. 25, 2017. [cited by applicant]
STN Registry No. 2058942-98-4, Entry date: Jan. 25, 2017. [cited by applicant]
STN Registry No. 2058934-50-0, Entry date: Jan. 25, 2017. [cited by applicant]
STN Registry No. 2058934-49-7, Entry date: Jan. 25, 2017. [cited by applicant]
STN Registry No. 1025885-32-8, Entry date: Jun. 5, 2008. [cited by applicant]